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Introduction: Metastasis-associated protein CD24 has been identi-
fied as a new prognostic factor and stem cell marker in the human
neoplasm. However, the importance of the CD24 in non-small cell
lung carcinomas (NSCLCs) has not been elucidated well.
Methods: We evaluated CD24 expression in 267 consecutive cases
of NSCLC by immunohistochemistry using a tissue microarray
technique and correlated with clinicopathologic parameters includ-
ing forthcoming (seventh) new tumor node metastasis classification.
Results: CD24-high expression was demonstrated in 87 of 267
(33%) and was associated with adenocarcinoma (ADC) histology
than in squamous cell carcinoma histology (64 of 165 39% vs. 20
of 88 23%; p  0.023). Patients with CD24-high tumors tended to
have a higher risk of disease progression (p  0.001) and cancer-
related death (p  0.002). Multivariate analysis proved CD24-high
expression as independent prognostic factors of disease progression
and cancer-related death (p  0.002, hazard ratio  1.78, 95%
confidence interval 1.23–2.58 and p 0.017, hazard ratio 1.93,
95% confidence interval 1.13–3.31). CD24-high expression had a
tendency to correlate with new pathologic stage (p-stage) (p 
0.089) rather than old p-stage (p  0.253). Performance status and
new p-stage, regardless of the tumor histology, were identified as
consistent independent prognostic factors of disease progression and
cancer-related death. However, age was related to a significantly
shorter cancer-specific survival in ADC only.
Conclusions: CD24 expression in NSCLC is associated with ADC
histology and disease progression and cancer-related death, indica-
tive of aggressive tumor behavior. Performance status and new
p-stage, to a lesser extent, age correlated with progression-free
survival and cancer-specific survival, regardless of tumor histology.
Key Words: Carcinoma, Non-small cell lung, Immunohistochem-
istry, Prognosis, CD24, Pathologic stage, Prognostic factors.
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Non-small cell lung carcinoma (NSCLC) is one of themost common cancers and the major cause of cancer-
related death in the world, with 1.3 million deaths worldwide
annually.1 The overall 5-year survival rate for lung cancer is
14%.2 Therefore, understanding the mechanism underlying
lung carcinogenesis is essential for better management of
lung cancer patients.
Currently, the most important conventional prognostic
factors for patient survival are tumor stage at the time of
diagnosis, including tumor size, pleura invasion, involvement
of regional lymph nodes, and metastatic spread to distant
organs. With the current tumor node metastasis (TNM) sys-
tem,3 however, patients within the same stage group may
have different prognoses, and especially, stage I lung cancers
and stage III lung cancers are biologically heterogeneous. In
this context, the last updated classification of the TNM
staging system for lung cancer, published in 1997,3 is under-
going revision. A new proposals for revision of the TNM
descriptors and stage groupings for lung cancer in the forth-
coming (seventh) edition of the International Union Against
Cancer and American Joint Committee on Cancer (AJCC)
TNM Classification of Malignant Tumors from the Interna-
tional Association for the Study of Lung Cancer (IASLC) has
just been proposed.4–9 According to the Prognostic Factors
Subcommittee of the International Staging Committee, age,
gender, and performance status (PS), in addition to stage,
were all found to be prognostic factors for survival.10,11
In addition to these clinicopathologic variables, in-
creased attention has focused on new molecular markers:
biologic substaging in a risk stratification strategy has been
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proposed.12 Biomarkers that are overexpressed during cancer
progression are of special interest because they may not only
be used to predict patient outcome but also serve as potential
targets in cancer therapy like epidermal growth factor recep-
tor (EGFR) gene, which provides new therapeutic options
with drugs specifically targeting epidermal growth factor
receptor.13–15
Metastasis-associated protein CD24 is a small, heavily
glycosylated cell surface protein that is attached to the cell
membrane by a glycosyl-phosphatidylinositol anchor.16–19
CD24 is expressed not only in developing20–22 or regenerat-
ing23 tissue but also in granulocytes, pre-B cells,24 keratino-
cytes,25 and renal tubules.26 Ral GTPases signaling are im-
portant mediators of transformation, tumorigenesis, and
cancer progression. CD24 is functionally relevant Ral-regu-
lated target27 and is involved in cell adhesion and metastatic
tumor spread. Interestingly, CD24 is expressed in many
human carcinomas including ovarian cancer,28,29 breast car-
cinoma,30,31 small cell lung carcinoma,24 bladder car-
cinoma,27 prostate cancer,32 urothelial carcinoma,33 and renal
cell carcinom.34 Moreover, high level of CD24 expression
detected by immunohistochemistry (IHC) has been found in
association with poor prognosis in human neoplasm.27–34
Recently, CD24 has gained new interest as cancer stem
cells,35 often coupled with migration and/or adhesion mole-
cules such as CD44,36 CD29,37 and CD31 (platelet-derived/
endothelial cell adhesion molecule).38–40
Although increased CD24 has been detected in several
human cancers, there is only one report of its prognostic
significance in NSCLC.41 In addition, the number of cases in
the previous study was limited, and their prognostic meaning
of patient survival was only evaluated according to old TNM
staging system.3 Therefore, it is important to validate the
CD24 expression using large scale samples according to the
forthcoming (seventh) new TNM stage classification.4
The purpose of this study was to clarify CD24 expres-
sion patterns in NSCLC by IHC and to correlate our findings
to clinicopathologic variables such as PS, age, and gender
including prognostic significance. In addition, we correlated
CD24 expression with forthcoming (seventh) new TNM
stage.
PATIENTS AND METHODS
Patients and Tissues
We retrospectively searched formalin-fixed and paraf-
fin-embedded tissues of 267 consecutively resected primary
NSCLC obtained from the Seoul National University Bun-
dang Hospital from May 2003 to July 2006. Causes of death
other than lung carcinoma and recurrent cases were excluded
from this study. None of the patients had received neoadju-
vant chemotherapy or irradiation preoperatively. The patients
with NSCLC consisted of 190 men and 77 women. The mean
age was 62.6 years (standard deviation, 10.6; range, 21–84
years), and the mean tumor size was 3.5 cm (standard
deviation, 2.0; range, 0.4–16 cm).
The hematoxylin and eosin-stained slides were re-
viewed in each case to confirm the original diagnosis by two
pathologists (H.J.L. and J.H.C.) independently, which was
based on the World Health Organization criteria.42 Tumor
specimens were histopathologically diagnosed as adenocar-
cinoma (ADC; n  165), squamous cell carcinoma (SCC;
n  88), adenosquamous cell carcinoma (n  7), large cell
neuroendocrine carcinoma (n  2), carcinoid tumor (n  2),
sarcomatoid carcinoma (n  2), and large cell carcinoma
(n  1). Lung ADCs showed marked heterogeneity, so all
tumor slides were reviewed, and the most representative
sections were selected from each specimen.
The pathologic stage (p-stage) was determined by cur-
rent TNM international staging system (adapted from the
AJCC TNM Cancer Staging Manual).3,43 They represented 61
stage Ia, 61 stage Ib, 15 stage IIa, 44 stage IIb, 49 stage IIIa,
20 stage IIIb, and 17 stage IV tumors according to the
guidelines of the AJCC. Conversely, they represented 61
stage Ia, 51 stage Ib, 48 stage IIa, 26 stage IIb, 62 stage IIIa,
5 stage IIIb, and 14 stage IV tumors according to the guide-
lines of the forthcoming (seventh) edition of the TNM Clas-
sification (Table 1).4 The medical records were collected
including age, gender, PS using the Zubrod scale,44 and
smoking history. Further data including progression of dis-
ease, patients’ survival status, and cause of death were ob-
tained from the patients’ medical records and/or interview
with the family of the patients. The median follow-up period
for all patients was 47.0 months, with a range of 1 to 74
months.
Construction of Tissue Microarray
For uniform and simultaneous protein expression anal-
ysis of multiple tissue samples, we prepared tissue microar-
rays (TMAs). Representative core tissue sections (2 mm in
diameter) were taken from the paraffin blocks and arranged in
new TMA blocks using a trephine apparatus (Superbiochips
Laboratories, Seoul, Korea). In cases with variable histologic
features, the most representative area was selected for TMA
construction. Six cores were sampled and included in the
TMA block from each patient.
Immunohistochemistry for CD24 Protein
CD24 expression was analyzed by IHC. Details of the
materials and methods used in this study were reported
previously34 and will be briefly described. From the TMA
blocks, 4-m thick sections were deparaffinized in xylene
TABLE 1. The Comparison of Pathologic Stage Determined
by Current (Sixth) TNM International Staging System and
Forthcoming (Seventh) Edition
Current (Sixth)3 Forthcoming (Seventh)4
Stage Ia 61 61
Stage Ib 61 51
Stage IIa 15 48
Stage IIb 44 26
Stage IIIa 49 62
Stage IIIb 20 5
Stage IV 17 14
Values are expressed as N.
TNM, tumor node metastasis.
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and rehydrated in graded alcohol. Antigen retrieval was
achieved by pressure cooking in 0.01 mol/liter citrate buffer
for 5 minutes. The primary CD24 antibody (Ab-2, clone
SN3b, Neomarkers, Fremont, CA) was diluted 1:100 and
incubated at room temperature for 1 hour. The immunohis-
tochemical reaction was visualized using the EnVision kit
(Dako, Carpinteria, CA) according to the manufacturer’s
protocol. Positive controls, consisting of cases with known
reactivity for antibody, and negative controls, obtained omit-
ting the primary antibody, were included. We also analyzed
25 nonneoplastic pulmonary parenchymal whole mount par-
affin sections adjacent to the NSCLC.
Immunohistochemical Assessment
CD24 expression was detected at the apical membrane
of normal bronchial epithelial cells and circumferential mem-
branous patterns of pneumocytes in the normal alveolar
walls. Tumor cells were judged as positive if cytoplasmic and
circumferential membranous staining was present. Immuno-
histochemical staining was separately and independently
evaluated by two investigators (H.J.L. and J.H.C.). In the rare
instance of a discrepancy in judgement, agreement was ob-
tained by discussion at a multihead microscope. At the time
of review, neither of these investigators were aware of the
clinicopathologic data of the NSCLCs, because all of the
slides had been coded. The staining intensity of CD24 was
semiquantitatively scored into four categories: 0, no positive
cell; 1, 1 to 10% positive cells; 2, 11 to 50% positive
cells; and 3, more than 50% positive cells.
Statistical Analysis
Statistical significance of the data obtained was inferred
using Statistical Package, SPSS version 15.0 for Windows
(SPSS Inc, Chicago, IL). Associations between the CD24
expression and the clinicopathologic characteristics were an-
alyzed using the Pearson 2 or Fisher’s exact test according to
test condition. Kaplan–Meier analysis was performed for
survival curves, and statistical significance was assessed
using the log-rank test. Progression-free survival was defined
as the time from the date of surgery to the last follow-up visit
or evidence of recurrence or metastasis of NSCLC. Cancer-
specific survival was defined as the time from the date of
surgery to the last follow-up visit or cancer-related death.
Univariate analysis of progression-free survival or cancer-
specific survival was performed using the Kaplan-Meier
method. Multivariate Cox proportional hazard regression
analysis was used to assess the prognostic significance of the
CD24 expression and the other clinicopathologic character-
istics on survival. Overall, 95% confidence intervals (CIs)
were used throughout the analysis. Statistical significance
was defined as p  0.05.
RESULTS
CD24 Immunoreactivity
In the nonneoplastic pulmonary parenchyma, all 25
sections expressed CD24 in the apical membrane of bronchial
epithelial cells and circumferential membrane of pneumo-
cytes in alveolar walls (Fig. 1A, B). The CD24 protein
expression in NSCLC appeared mainly in the cytoplasm and
circumferential membrane (Fig. 1C–F). The cytoplasmic
CD24 expression in the NSCLC tissue was significantly
greater than that in the nonneoplastic pulmonary parenchyma
(p  0.001). After evaluation of the 267 immunostained
NSCLC specimens, 78 (29%) showed no positivity, 102
(38%) 1 positivity, 41 (15%) 2 positivity, and 46 (17%)
3 positivity. For the statistical analysis, the cases were
subdivided into a CD24-low expression group (0 and 1,
n 180 67%) and a CD24-high expression group (2 and
3, n 87 33%).
Correlations between CD24 Expression and
Clinicopathologic Parameters
CD24-high positivity correlated with ADC histology
better than in SCC histology (64 of 165 39% vs. 20 of 88
23%; p  0.023). Weak correlations between CD24-high
expression level and newly proposed advanced p-stage (p 
0.089), younger age (p  0.067), and pleura invasion (p 
0.081) were also found without reaching formal statistical
significance. Other clinicopathologic variables, including sex
(p  1.000), tumor size (p  0.149), smoking (p  0.786),
PS (p  0.609), venous invasion (p  0.441), lymphatic
invasion (p  0.150), perineural invasion (p  0.476), old
tumor status (p  0.242), old p-stage (p  0.253), new tumor
status (p  0.159), and new M category (p  0.394) did not
correlate with CD24 expression (Table 2). CD24-high ex-
pression had a tendency to correlate with new p-stage (p 
0.089) rather than old p-stage (p  0.253).
Survival Analysis
At the time of analysis, the number of cancer-specific
deaths and patients with disease progression was 58 and
119, respectively. On univariate survival analysis, the
conventional prognostic parameters, including tumor size,
PS, pleura invasion, venous invasion, lymphatic invasion,
old TNM, old p-stage, new TNM, and new p-stage reached
significance for progression-free and cancer-specific sur-
vival (Table 3 and Fig. 2A, B). CD24-high expression
group had a significantly shorter progression-free and
cancer-specific survival than did the CD24-low expression
group (p  0.001 and p  0.002, respectively; Fig. 3A, B).
Older age also had a significantly shorter cancer-specific
survival (p  0.002). To evaluate whether CD24 positivity
in NSCLC is an independent predictor of progression-free
and cancer-specific survival, a multivariate analysis using
the Cox proportional hazard model was performed and
included venous invasion, lymphatic invasion, PS, age,
new p-stage, and CD24 expression. All variables with a
p  0.05 in univariate analysis were included in a multi-
variate Cox model. Four variables, new p-stage (p  0.001
and p  0.001; progression-free and cancer-specific sur-
vival, respectively), PS (p  0.001 and p  0.001; pro-
gression-free and cancer-specific survival, respectively),
age (p  0.012; only in cancer-specific survival), and
CD24 expression (p  0.002 and p  0.017; progression-
free and cancer-specific survival, respectively) were sig-
nificant prognostic factors for NSCLC patients. Multivar-
iate analysis proved CD24-high expression as independent
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prognostic factors of disease progression and cancer-re-
lated death (p  0.002, hazard ratio  1.78, 95% CI 
1.23–2.58 and p  0.017, hazard ratio  1.93, 95% CI 
1.13–3.31, respectively; Table 4).
PS and new p-stage, regardless of the tumor histology,
were identified as consistent independent prognostic factors
of disease progression and cancer-related death (Tables 5 and
6). However, age was related to a significantly shorter cancer-
specific survival in ADC only. CD24-high expression group
reached prognostic significance for progression-free and can-
cer-specific survival, especially in SCC.
DISCUSSION
In this study, we examined the association of CD24
expression of NSCLC with clinicopathologic parameters
including survival significance in comparison with forth-
coming (seventh) new TNM stage. Kristiansen et al.41 have
reported that CD24-high expression was 45% of 89 sam-
ples (ADC 49 cases and SCC 40) with cytoplasmic and
membraneous staining pattern in NSCLC. In their study,
normal lung parenchyma showed a strong membraneous
staining pattern of pneumocytes, whereas bronchial epi-
thelium was mostly negative. They revealed the correlation
between CD24 activation and preferentially ADC histol-
ogy (p  0.001). They also found CD24 expression to be
an independent predictor of shortened patient survival as
evidenced by univariate and multivariate analyses in
NSCLC. In this study, we expanded the number of cases
(total 276 cases; ADC 165, SCC 88, and others 14) and
included a survival analysis in the forthcoming (seventh)
new TNM classification. We found that all 25 nonneoplas-
tic pulmonary parenchymal sections expressed CD24 in
the apical membrane of bronchial epithelial cells and
circumferential membrane of pneumocytes in alveolar
walls. The different expression patterns of normal bron-
chial epithelium between two studies might be due to use
of not TMA but whole mount section. We used whole
mount section, which was more accurate for IHC interpre-
tation. In agreement with the previous study,41 the CD24
protein expression in NSCLC appeared mainly in the
FIGURE 1. Immunohistochemical staining of
CD24 expression in NSCLC: (A) normal bronchial
epithelium, (B) normal alveolar walls, (C) ADC;
CD24-high expression, (D) ADC; CD24-low ex-
pression, (E) SCC; CD24-high expression, and (F)
SCC; CD24-low expression. CD24 was expressed
cytoplasm and/or circumferential membranes in
the tumor cells (200). NSCLC, non-small cell
lung carcinoma; ADC, adenocarcinoma; SCC,
squamous cell carcinoma.
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cytoplasm and circumferential membrane. The CD24-high
expression showed 87 of 267 (33%) cases and significantly
higher in ADC histology (p  0.023). Multivariate anal-
ysis results of CD24-high expression as independent prog-
nostic factors of disease progression and cancer-related
death are concordant with the results of a previous study.
CD24-high expression has been known to be involved in
the tumor progression and worse biologic activity. There-
fore, CD24 expression might be a novel prognostic marker
for tumor recurrence or metastasis in NSCLC.
Progression of NSCLC might be associated with the
strengthening of activation of CD24, especially cytoplasmic
expression. The question then becomes how the strengthen-
ing of CD24 activation is related to the advancement of
NSCLC. One possible mechanism is the function of the
CD24, as a ligand to P-selectin, an adhesion receptor ex-
pressed on activated endothelial cells and platelets, and could
thus enhance the metastatic potential of CD24-expressing
tumor cells.19,45–48 Therefore, Kristiansen et al.41 hypothe-
sized that the decreased survival of NSCLC patients with
strongly CD24-positive tumors is related to an enhanced
propensity of hematogenous metastasis formation, which
might be P-selectin mediated.49,50
Recently, there have been many refinements to the
techniques available for clinical staging, principally the rou-
tine use of high-resolution computed tomography resulted in
frequent detection of early small lung cancer, which overall
5-year survival rate was surprisingly high.51,52 Moreover,
stage III NSCLC patients separated into IIIa and IIIb by the
1997 international staging system3 is heterogeneous, includ-
ing surgically resectable tumors and unresectable diseases
treated by chemotherapy and radiotherapy. Increasingly re-
ports were challenging some of the descriptors and suggest-
ing revised stage groupings. Therefore, in the IASLC Lung
Cancer Staging Project, there were proposals for the revision
of the TNM stage groupings in the forthcoming (seventh)
edition of the TNM classification of malignant tumors.4
According to the IASLC staging committee, PS, age, gender,
and stage were confirmed as important prognostic factors in
surgically resected NSCLC and tumor histology was less
important.10,11 We found that CD24-high expression
TABLE 2. Distribution of CD24 Status in 267 Patients with
NSCLC
Variables N (%) CD24-Low CD24-High p
Total 267 (100) 180 (67) 87 (33)
Sex
Male 190 (71) 128 (67) 62 (33) 1.000
Female 77 (29) 52 (68) 25 (32)
Age (yr)
65 120 (45) 88 (73) 32 (27) 0.067
65 147 (55) 92 (63) 55 (37)
Tumor size (cm)
3 120 (45) 75 (63) 45 (37) 0.149
3 147 (55) 105 (71) 42 (29)
Histology
ADC 165 (62) 101 (61) 64 (39) 0.023
SCC 88 (33) 68 (77) 20 (23)
Others 14 (5) 11 (79) 3 (21)
Performance status
0 175 (66) 115 (66) 60 (34) 0.609
1 62 (23) 45 (73) 17 (27)
2 30 (11) 20 (67) 10 (33)
Smoking
Nonsmoker 95 (36) 63 (66) 32 (34) 0.786
Smoker 172 (64) 117 (68) 55 (32)
Pleura invasion
Absent 165 (62) 118 (72) 47 (28) 0.081
Presenta 102 (38) 62 (61) 40 (39)
Venous invasion
Absent 233 (87) 159 (68) 74 (32) 0.441
Present 34 (13) 21 (62) 13 (38)
Lymphatic invasion
Absent 141 (53) 101 (72) 40 (28) 0.150
Present 126 (47) 79 (63) 47 (37)
Perineural invasion
Absent 245 (92) 167 (68) 79 (32) 0.476
Present 22 (8) 13 (59) 9 (41)
New tumor status
T1 84 (32) 62 (74) 22 (26) 0.159
T2 131 (49) 89 (68) 42 (32)
T3 41 (15) 22 (54) 19 (46)
T4 11 (4) 7 (64) 4 (36)
New pathologic
stage
I 112 (42) 83 (74) 29 (26) 0.089
II 74 (28) 51 (69) 23 (31)
III 67 (25) 38 (57) 29 (43)
IV 14 (5) 8 (57) 6 (43)
a Visceral and/or parietal invasion.
NSCLC, non-small cell lung carcinoma; ADC, adenocarcinoma; SCC, squamous
cell carcinoma.
TABLE 3. Univariate Analysis Results of Progression-Free
Survival and Cancer-Specific Survival in 276 Patients with
NSCLC
Univariate
p
Progression-Free
Survival
Cancer-Specific
Survival
CD24 expression (low vs. high) 0.001 0.002
Sex (male vs. female) 0.893 0.204
Age (65 vs. 65 yr) 0.167 0.002
Histology (ADC vs. SCC) 0.820 0.976
Smoking (nonsmoker vs. smoker) 0.812 0.250
Size (3 vs. 3 cm) 0.001 0.001
Performance status (0, 1, 2) 0.001 0.001
Pleura invasiona 0.001 0.002
Venous invasiona 0.001 0.001
Lymphatic invasiona 0.004 0.001
Perineural invasiona 0.203 0.133
New p-stage (I, II, III, IV) 0.001 0.001
a Absent vs. present.
NSCLC, non-small cell lung carcinoma; ADC, adenocarcinoma; SCC, squamous
cell carcinoma; p-stage, pathologic stage.
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tended to be correlated with new p-stage (p  0.089) rather
than old p-stage (p  0.253) without reaching formal
statistical significance. The question then becomes why
new p-stage is more related to CD24-high expression
rather than old p-stage. One possible explanation is that
forthcoming (seventh) edition TNM classification provides
more precise criteria to specimen processing, specifically
looking at tumor size and how to deal with multiple
tumors.53 On multivariate analyses, CD24-high expres-
sion, PS, and new p-stage, to a lesser extent, age correlated
with progression-free survival and cancer-specific sur-
vival, regardless of tumor histology.
FIGURE 2. Kaplan-Meier survival curve for new forthcoming (seventh) pathologic stage: (A) progression-free survival (p 
0.001) and (B) cancer-specific survival (p  0.001) in NSCLC (n  267). NSCLC, non-small cell lung carcinoma.
FIGURE 3. Kaplan-Meier survival curve for CD24: (A) progression-free survival (p  0.001) and (B) cancer-specific survival
(p  0.002) in NSCLC (n  267). NSCLC, non-small cell lung carcinoma.
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There are some limitations to generalize these re-
sults. First, we cannot exclude selection bias because all
the enrolled patients were surgically resectable. Second,
PS is nearly either PS 0 or 1, or 2. Third, this is a
retrospective study. Despite these limitations, this is the
first study to examine CD24 expression in a large number
of NSCLC patients and to confirm the role of prognostic
factors such as PS, age, and stage according to forthcom-
ing (seventh) new TNM classification.
CD24 has gained new interest as cancer-stem cells35
and a potentially important prognostic marker. As a conse-
quence, presence of CD24 antigen could be an important key
to study the biology of NSCLC and can represent an impor-
tant and useful tool to facilitate the development of new
diagnostic and future therapeutic approaches to eliminate
CD24 function in cancer cells.
CONCLUSIONS
This study objectively demonstrated the prognostic
significance of CD24 expression using large number cases
of NSCLC and evaluated CD24 expression using current
TNM classification and forthcoming new TNM stage clas-
sification, respectively. Our results showed significantly
greater cytoplasmic and/or circumferential membranous
expression of CD24 in NSCLC than in nonneoplastic
TABLE 4. Multivariate Analysis Results of Progression-Free Survival and Cancer-Specific Survival
in 276 Patients with NSCLC
Cox Regression
Progression-Free Survival Cancer-Specific Survival
p HR 95% CI p HR 95% CI
CD24 (low vs. high) 0.002 1.78 (1.23–2.58) 0.017 1.93 (1.13–3.31)
Age (65 vs. 65 yr) 0.012 2.07 (1.17–3.65)
Venous invasiona 0.610 1.14 (0.69–1.87) 0.835 1.07 (0.55–2.08)
Lymphatic invasiona 0.279 0.81 (0.55–1.19) 0.223 1.44 (0.80–2.58)
Performance status (0, 1, 2) 0.001 1.70 (1.34–2.17) 0.001 2.20 (1.54–3.14)
New p-stage (I, II, III, IV) 0.001 2.54 (2.05–3.14) 0.001 2.65 (1.91–3.69)
a Absent vs. present.
HR, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung carcinoma; p-stage, pathologic stage.
TABLE 5. Univariate Analysis Results of Progression-Free Survival and Cancer-Specific Survival in
165 Patients with ADC and 88 Patients with SCC, Respectively
Univariate
ADC (p) SCC (p)
Progression-Free
Survival
Cancer-Specific
Survival
Progression-Free
Survival
Cancer-Specific
Survival
CD24 expression (low vs. high) 0.008 0.301 0.008 0.005
Age (65 vs. 65 yr) 0.163 0.001 0.590 0.102
Performance status (0, 1, 2) 0.001 0.001 0.012 0.002
New p-stage (I, II, III, IV) 0.001 0.001 0.001 0.001
ADC, adenocarcinoma; SCC, squamous cell carcinoma; p-stage, pathologic stage.
TABLE 6. Multivariate Analysis Results of Progression-Free Survival and Cancer-Specific Survival
in 165 Patients with ADC and 88 Patients with SCC, Respectively
Progression-Free Survival Cancer-Specific Survival
p HR 95% CI p HR 95% CI
ADC (n  165) Cox regression
CD24 (low vs. high) 0.061 1.570 (1.01–2.23)
Age (65 vs. 65 yr) 0.013 2.490 (1.21–5.13)
Performance status (0, 1, 2) 0.002 1.711 (1.22–2.40) 0.001 2.431 (1.51–3.91)
New p-stage (I, II, III, IV) 0.001 2.442 (1.86–3.20) 0.001 2.730 (1.86–4.02)
SCC (n  88) Cox regression
CD24 (low vs. high) 0.045 2.045 (1.01–4.12) 0.010 3.688 (1.36–10.01)
Performance status (0, 1, 2) 0.045 1.547 (1.01–2.37) 0.031 2.032 (1.07–3.86)
New p-stage (I, II, III, IV) 0.001 2.330 (1.49–3.64) 0.002 2.864 (1.49–5.51)
HR, hazard ratio; CI, confidence interval; ADC, adenocarcinoma; SCC, squamous cell carcinoma; p-stage, pathologic stage.
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pulmonary parenchyma. A high expression of CD24 was a
negative independent prognostic factor for progression-
free and cancer-specific survival in NSCLC. PS and new
p-stage, to a lesser extent, age correlated with progression-
free survival and cancer-specific survival, regardless of
tumor histology.
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